Objective. Herpes zoster (HZ) is an opportunistic infection caused by varicella-zoster virus and observed with increasing frequency in patients receiving immunosuppressive therapies. The literature has suggested that the risk of stroke may increase shortly after HZ, but little is known about this association in patients with autoimmune diseases, who are at increased risk of both zoster and stroke.
Objective. Herpes zoster (HZ) is an opportunistic infection caused by varicella-zoster virus and observed with increasing frequency in patients receiving immunosuppressive therapies. The literature has suggested that the risk of stroke may increase shortly after HZ, but little is known about this association in patients with autoimmune diseases, who are at increased risk of both zoster and stroke.
Methods. Medicare data from January 1, 2006 through December 31, 2013 were used to identify patients with autoimmune diseases. The outcome of interest was hospitalized stroke. The hypothesis tested was that the incidence of stroke immediately following HZ is increased compared to the incidence of stroke at later time points. Secondary analyses included assessment of the impact of antiviral therapy on subsequent stroke, as well as the influence of varicella-zoster virus-related complications on stroke incidence.
Results. The crude incidence of stroke ranged from a high of 2.30 per 100 patient-years (95% confidence interval [95% CI] 0.96-5.52) within 90 days of HZ in patients who had HZ-related cranial nerve complications and did not receive treatment to a low of 0.87 per 100 patient-years (95% CI 0.75-1.02) at 366-730 days in those without complication who received antiviral treatment. After multivariable adjustment for multiple stroke-related factors, the overall incidence rate ratio (IRR) for stroke in the first 90 days after HZ was 1.36 (95% CI 1.10-1.68) compared to stroke occurring at 366-730 days after HZ. The risk was greater for patients with zoster and cranial nerve complications (IRR 2.08 [95% CI 0.99-4.36]). Prompt antiviral therapy was associated with lower incidence of subsequent stroke (IRR 0.83 [95% CI 0.70-0.98]).
Conclusion. In patients with autoimmune diseases, incident HZ was associated with as much as a 2-fold increased risk of stroke in the subsequent few months. These data underscore the urgency of developing strategies for reducing the risk of varicella-zoster virus.
Herpes zoster (HZ) infection, also known as shingles, is caused by reactivation of latent varicellazoster virus infection generally acquired decades earlier. HZ has been variably considered an opportunistic infection; while it clearly occurs in "normal" hosts, it is readily understood that diminished cell-mediated immunity leads to zoster (1) . While more than half of the individuals developing zoster are over the age of 60 years, patients with autoimmune disease and particularly those receiving immunosuppressive therapy are at 1.5-2 times the risk of developing HZ as compared to healthy adult controls (2) .
In general, HZ manifests as a painful vesicular rash that, even when uncomplicated, can be highly symptomatic. HZ is, however, often pernicious, with frequent complications, the most common of which is postherpetic neuralgia, which can often lead to long-term pain, depression, and disability (1, 3) . In immunocompromised hosts, even more severe complications can be observed, including vasculopathy, myelitis, motor nerve involvement, cranial nerve palsies, and ocular involvement (4). The annual health care costs related to HZ have been estimated to be in the hundreds of millions of dollars, and this does not begin to account for the pain and reduced quality of life caused by the disease (5).
While most complications (aside from postherpetic neuralgia) are rare, a series of recent epidemiologic studies suggest that HZ may be associated with a more common and serious complication in the form of an increased risk of stroke. These studies, which used various methodologies and were performed on 3 continents, demonstrated that in patients with HZ, there is a statistically and clinically significant risk of stroke, ranging from 30% to 430%, peaking in the first few weeks after HZ and tapering off over the ensuing year (6) (7) (8) (9) (10) (11) .
Given that these studies examining the relationship between HZ and stroke have been performed in the general population, we designed our study to examine a patient population traditionally considered to be at increased risk of HZ (i.e., those with immunosuppressive illnesses) to determine whether they too were at increased risk of stroke. Secondarily, we examined whether early antiviral therapy in patients with HZ had an ameliorative effect by reducing the incidence of stroke.
PATIENTS AND METHODS
Study design and data sources. We conducted a retrospective cohort study using Medicare claims data from January 1, 2006 through December 31, 2013 for 100% of patients with ankylosing spondylitis, inflammatory bowel disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis. Medicare is a US federal benefit program that provides health insurance to ;93% of US adults 65 years of age and older; it also provides insurance coverage for ;7 million people younger than 65 years who have disabling conditions (e.g., rheumatoid arthritis) or end-stage renal disease (12) . The Institutional Review Board of the University of Alabama at Birmingham approved the study, and the study data were governed by a Data Use Agreement from the Center for Medicare and Medicaid Services.
Cohort. Our study cohort consisted of patients experiencing an episode of HZ, as identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for zoster (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.39855/abstract) for either an inpatient or an outpatient health care provider encounter. Follow-up started on the date HZ was diagnosed (the "index date"). To be included in the analysis, we also required all patients to have at least 12 consecutive observable months (enrolled in Medicare Parts A, B, and D, but not Part C) prior to the index date (baseline) and at least 1 of the 5 included inflammatory diseases defined by 2 ICD-9-CM diagnosis codes separated by 7 days and within 1 year, using all available data prior to the index date. Patients with any inpatient or outpatient health care provider visit claim with any diagnosis code for stroke (using all available data prior to the index date) or antiviral treatment for zoster during the baseline were excluded. Follow-up ended at the earliest of the following dates: a hospitalized ischemic or hemorrhagic stroke, 24 months after the index date, loss of Medicare coverage, or the end of study (December 31, 2013) .
Exposure and risk windows. The zoster phenotype was classified into 1 of 3 mutually exclusive categories based on diagnosis codes (Supplementary Table 1 ) within 7 days after the first diagnosis code (hierarchically) as follows: zoster with cranial nerve complication, zoster with other complication, and zoster without complication. If patients met criteria for more than 1 phenotype, they were assigned to the highest (i.e., with complications). This classification was used to allow for a subgroup analysis testing the hypothesis that zoster with cranial nerve complications would have a stronger association with stroke than would zoster without complications. The risk windows used for stroke ascertainment were defined as the time since the index date (0-90 days, 91-365 days, and 366-733 days) and were selected based on published literature showing HZ stroke associations in a noninflammatory disease population (6) (7) (8) (9) (10) (11) . Antiviral treatment for HZ (i.e., acyclovir, valacyclovir, famciclovir, foscavir, ganciclovir) was identified within 7 days after the zoster diagnosis. The positive predictive value of a zoster diagnosis alone for identifying incident zoster exceeds 85% and is even higher when antiviral drug use is required (11, 13) .
Outcome assessments. Hospitalized stroke was defined as a diagnosis code of stroke (Supplementary Table 1) in the primary or nonprimary position on a hospital claim. A subgroup analysis was conducted that was limited to hospitalized ischemic stroke.
Covariates. We evaluated demographic characteristics, including age, sex, and race. In addition to the inflammatory conditions of interest, we also studied comorbid conditions (Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.39855/ abstract), including diabetes mellitus, hypertension, atrial fibrillation, hyperlipidemia, obesity, transient ischemic attack, tobacco use, and carotid artery disease. These were assessed using ICD-9 diagnosis codes and/or procedure codes using a 12-month baseline period. Medications of interest included biologic diseasemodifying antirheumatic drugs (DMARDs) (yes/no), nonbiologic DMARDs (yes/no), and mean glucocorticoid dose averaged over the 183 days prior to the start of follow-up. Covariates were selected based upon content knowledge of risk factors for stroke or zoster.
Statistical analysis. We generated descriptive statistics for demographic characteristics, comorbidities, and medication use, stratified by each of the 3 zoster phenotypes. We calculated incidence rates (IRs) for subsequent hospitalized stroke by dividing the number of events by the number of patient-years, and we generated 95% confidence intervals (95% CIs) using Poisson regression for each exposure group and risk window. Generalized linear models for repeated measures were used to estimate incidence rate ratios (IRRs) and 95% CIs. We conducted a pooled analysis that included patients regardless of whether they were treated with antiviral medications, and included this medication use as a term in the multivariable model to estimate the effect of antiviral medication for zoster on subsequent stroke. Finally, as part of a sensitivity analysis, we used Cox proportional hazards models to compute IRRs that adjusted for the competing risk of death. All analyses were performed using SAS 9.4 software (SAS Institute).
RESULTS
We identified 267,906 patients with inflammatory diseases (any 1 diagnosis code) who developed HZ. The following patients were excluded: those without at least 12 months of enrollment before the first zoster diagnosis (n 5 169,135), those who used antiviral medication within 440 CALABRESE ET AL 12 months before the index date (n 5 14,633), those who did not meet our study criteria requirement for an autoimmune inflammatory disease (n 5 33,272), and those with a diagnosis of stroke prior to the index date (n 5 7,339). The final cohort consisted of 43,527 patients. Among these individuals, 3,080 had zoster with cranial nerve complication, 4,494 had zoster with other complication, and 35,953 had zoster without complication ( Figure 1 ). Demographic features, comorbid conditions, and medication use were similar among the 3 zoster groups (Table 1 ).
In the overall cohort (Table 2) , the crude IR of stroke declined from 1.24 per 100 patient-years (95% CI 1.05-1.48) within 0-90 days of zoster to 0.94 per 100 patient-years (95% CI 0.83-1.06) in days 366-730 postzoster. In the antiviral-treated zoster subgroup, the IRs of stroke declined from 1.13 per 100 patient-years (95% CI 0.92-1.39) in the 0-90 day risk window to 0.89 per 100 patient-years (95% CI 0.77-1.03) in the 366-730 day risk window. The IRs of stroke were numerically higher in the untreated zoster subgroup than in the group treated with antivirals and followed a similar pattern. They declined from 1.60 per 100 patient-years (95% CI 1.17-2.20) in 0-90 days to 1.10 per 100 patient-years (95% CI 0.86-1.39) in the 366-730 day interval. The stroke incidence rates in the 91-365 day risk window were intermediate between these other 2 risk windows.
In the cohort of patients with zoster who had cranial nerve complication, the IRs of stroke were numerically greater and showed large changes in risk over time. The IRs were highest in the days 0-90 risk window, from 2.29 per 100 patient-years (95% CI 1.43-3.69) within 0-90 days to 1.37 per 100 patient-years (95% CI 0.94-2.00) in the 366-730 day window (Table 2 ). In the antiviral-treated subgroup, IRs of stroke declined from 2.29 per 100 patient-years (95% CI 1.30-4.04) within 0-90 days to 1.17 per 100 patient-years (95% CI 0.72-1.91) in the 91-365 day risk window. The corresponding IRs in the same 3 risk windows among untreated patients were 2.30 per 100 patient-years (95% CI 0.96-5.52), 1.62 per 100 patientyears (95% CI 0.84-3.11), and 1.94 per 100 patient-years (95% CI 1.07-3.50). 1 Observable coverage represents enrollment in Medicare Parts A, B, and D, but not Part C, for 12 months prior to the diagnosis of herpes zoster. 2 Paired diagnosis codes consisted of 2 International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes for an inflammatory disease (ankylosing spondylitis, inflammatory bowel disease, psoriasis, psoriatic arthritis, or rheumatoid arthritis) separated by 7 days and occurring within 365 days. In the cohort of patients with zoster with complication other than cranial nerve involvement, patterns were similar but smaller in magnitude compared to those with cranial nerve complications ( Table 2 ). In the antiviral-treated subgroup, the IRs declined quickly from 1.98 per 100 patient-years (95% CI 1.13-3.49) in the 0-90 day window to 1.29 per 100 patient-years (95% CI 0.83-2.00) in the 91-365 days window, and further declined to 0.90 per 100 patient-years (95% CI 0.53-1.52) in the 366-730 days window ( Table 2 ). Rates of stroke among patients with zoster but without any zoster-related complications were smaller in magnitude and showed smaller trends over time (Table 2) . Overall, the majority of strokes in the overall analysis were ischemic (87%), and a sensitivity analysis with hospitalized ischemic stroke as the outcome revealed that the patterns were similar to those in the main analysis that included all strokes (data not shown).
In the multivariable adjusted results in the overall cohort (Table 3) Results from the sensitivity analysis that adjusted for the competing risk of death were consistent with the primary results (data not shown).
All adjusted IRRs were recalculated using as reference the time window of 1-2 years after zoster without complication (Figure 2 ). The IRRs were greatest for zoster with cranial nerve complications, particularly in the 0-90 day risk window after zoster. For these individuals, the adjusted IRRs exceeded 2. Later time windows were not associated with significantly increased risk. Trends were similar for patients who had zoster with other complications, although the magnitude of the IRRs in the 0-90 day window was somewhat lower, albeit still statistically significant. No results for any risk window were significant among patients who had zoster without complications.
DISCUSSION
In this large cohort of older patients with autoimmune and inflammatory diseases, we found a significantly elevated and time-dependent risk of hospitalized stroke following HZ, particularly among those who had HZrelated complications including cranial nerve involvement. Based upon the risk windows we examined (0-90 days, 90-365 days, and beyond 365 days), risk was greatest early and declined over time. Patients treated for HZ had a lower risk of stroke than those not treated, and this effect was more pronounced among those with HZrelated complications.
These results documenting HZ as a risk factor for stroke are consistent with those of several previous studies performed in the general population (6-11), though they did not specifically address this vulnerable population. In a study using the Taiwan National Health Research Institute database with matched controls, Kang et al (7) demonstrated an adjusted hazard rate of stroke of 1.31 for the 12 months following infection. In a subsequent study using a follow-on cohort from the same database with age-and sex-matched controls and adjusted for cardiovascular risks, Lin et al (14) found that patients with herpes zoster ophthalmicus had a 4.52-fold increase in stroke over a 1-year follow-up period, but importantly, patients with rheumatoid arthritis were excluded. A Danish study (9) analyzing 117,926 patients demonstrated an increased risk of stroke of 126% in the first 2 weeks from the onset of the infection and 17% from 2 weeks to 1 year. Langan et al (8) examined more than 6,000 patients over the age of 18 years with a history of HZ and stroke and compared the incidence of stroke after HZ to that in other time periods. They found that stroke increased after HZ, with an age-adjusted incidence rate of 1.63 over weeks 1-4, gradually decreasing over weeks 5-26. Similar to our study, a stronger effect was observed with herpes zoster ophthalmicus, rising to a .3-fold rate 5-12 weeks following infection.
Using an alternative approach, Breuer et al (6) performed a retrospective study of 106,601 HZ cases and 213,202 controls matched for age, sex, and general practice in the UK. Cox proportional hazard models were used to adjust for multiple cardiovascular risk factors including smoking (15) . Overall risk factors for vascular disease were increased in HZ patients, but hazard ratios were also increased in the overall group for transient ischemic attack and myocardial infarction, but not stroke. In a subset of subjects younger than 40 years, stroke was increased over the study period, with an adjusted hazard ratio of 2.42. Three other recent studies of alternative design including 1 single health system analysis (11, 16) and 2 registry-based cohort studies (10, 17) produced similar findings.
Our study has added to these recent investigations in several ways. First, ours is the first study to specifically examine an immunosuppressed patient population. This is particularly relevant given that such patients have been demonstrated to have a 1.5-2.0 times increased incidence of HZ over that in nonimmunosuppressed patient populations of similar age (2) . Second and consistent with several other studies (6) (7) (8) 14, 17) , we demonstrated that more serious and complex forms of HZ are attended by the highest rates of stroke. We performed this analysis by separating HZ by ICD code into zoster without complications as well as zoster with complications. We further divided zoster with complications into zoster with cranial nerve complications (identified by specific ICD-9 codes) and zoster with other complications (identified by any of the remaining 17 ICD-9 codes [see Supplementary Table 1] ). This latter group included mostly postherpetic neuralgia and other nonspecific designations. The rationale for this segregation relates to the known capacity of varicella to establish latency in cranial nerve ganglia, especially cranial nerve V, and spread retrograde via sensory nerve fibers to the cerebral circulation (18) .
In our adjusted analyses, we examined the effects of several important cardiovascular risk factors, including age, sex, race, diabetes mellitus, hypertension, atrial fibrillation, transient ischemic attack, and glucocorticoid use, which, consistent with previous studies (6) (7) (8) (9) (10) (11) , revealed minimal confounding effects. We believe that the consistent findings of our and other recent studies identifying risk of stroke from HZ is even further strengthened by biologic plausibility given the capacity of the virus to replicate in arteries and produce disease (19) . Varicella has also long been associated with the rare occurrence of stroke in children in the time period following primary infection (20, 21) . In addition, a rare syndrome of focal arteritis has been described in individuals with HZ ophthalmicus in the weeks and months following infection; it has also been linked to a spectrum of vascular disorders involving the central nervous system found predominantly, but not exclusively, in immunosuppressed individuals (4, 22) . Finally, zoster has recently been identified in the temporal arteries of patients undergoing biopsy for suspected giant cell arteritis (23) . While these observations support a likely role of HZ in the development of stroke, we have no pathology data to support speculation on the immunopathogenic mechanisms involved, though a virally driven inflammatory and/or procoagulant effect are possible. Further studies exploring pathogenic mechanisms are urgently needed given the implications of the large number of cases described and the implicit burden of morbidity and mortality linked to stroke.
There are several important limitations of our study. We were not able to confirm the diagnosis of zoster from examination of medical records, although our criteria for the primary analysis (combining ICD-9 diagnosis plus antiviral therapy) has been shown to have a high positive predictive value (.85%). Another limitation is that while we attempted to define the anatomic distribution and type of strokes in our population to determine if anatomic or pathologic trends could be identified, less than half of the 444 CALABRESE ET AL stroke events had sufficient details reported for such an analysis. We recognize the possibility that declining trends in stroke over time might be expected simply due to depletion of those susceptible, where the sickest patients are more likely to have serious adverse events (e.g., stroke) early. However, we would not expect that to be differential by zoster phenotype nor by receipt of antiviral treatment. Indeed, in the large subgroup of patients with zoster without complications who received antiviral therapy (n 5 403), there was essentially no time trend in the rate of stroke. Finally, while it would be desirable to examine the effects of HZ on stroke risk in younger patients, which has been demonstrated to be particularly elevated in at least 1 study (6), our analysis was limited to the age of the Medicare beneficiaries (mean age 71 years). We therefore believe our findings are conservative given age-related risk factors for stroke in this cohort that would attenuate the associations of interest. In younger patients, we hypothesize that the HZ-related relative effect on stroke risk is greater than that observed in this analysis. Given the public health implications of these observations, new urgency should be directed at increasing the rate of administering vaccinations for zoster in vulnerable populations. The proportion of older patients in our study who received vaccination was only 5%, which was minimally different from that in years past (24) . It is conceivable that an additional downstream benefit of preventing HZ may now include a lower risk of stroke, though this hypothesis remains speculative. Recent studies have demonstrated that the risk of zoster is 1.5-2.0 times elevated in patients with autoimmune diseases as compared to older populations (2), affirming the vulnerability of patients with autoimmune inflammatory diseases. Additional analysis from this same study (2) identified clinically meaningful elevations of HZ risk beginning at age 40 years that were comparable or higher than the risk of HZ in healthy older people ages 60 years and older, implying that serious consideration should be given to recommending vaccination at a lower age than 60 years, which is the current Advisory Commmittee on Immunization Practices-recommended minimum age for vaccination (25) or the Food and Drug Administration-approved age of 50 years, as was recently recommended in the 2015 updated treatment guidelines for rheumatoid arthritis (26) . In addition, many patients with autoimmune inflammatory diseases may have additional obstacles to vaccination, including the use of biologic agents (26) . Thus, the results of ongoing studies on the safety of the live zoster vaccine in the setting of tumor necrosis factor inhibitor therapy (27) and the further study of the safety and effectiveness of zoster vaccines in high-risk populations are clearly needed.
